241 related articles for article (PubMed ID: 19220837)
1. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Ames E; Hallett WH; Murphy WJ
Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
[TBL] [Abstract][Full Text] [Related]
3. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
5. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
Cancer Immunol Immunother; 2013 Aug; 62(8):1359-68. PubMed ID: 23689729
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Shen L; Au WY; Guo T; Wong KY; Wong ML; Tsuchiyama J; Yuen PW; Kwong YL; Liang RH; Srivastava G
Blood; 2007 Jul; 110(1):469-70. PubMed ID: 17579189
[No Abstract] [Full Text] [Related]
10. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
[TBL] [Abstract][Full Text] [Related]
11. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
Schumacher LY; Vo DD; Garban HJ; Comin-Anduix B; Owens SK; Dissette VB; Glaspy JA; McBride WH; Bonavida B; Economou JS; Ribas A
J Immunol; 2006 Apr; 176(8):4757-65. PubMed ID: 16585569
[TBL] [Abstract][Full Text] [Related]
12. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
[TBL] [Abstract][Full Text] [Related]
13. Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.
Lundqvist A; Su S; Rao S; Childs R
J Immunol; 2010 Feb; 184(3):1139-42. PubMed ID: 20026740
[TBL] [Abstract][Full Text] [Related]
14. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
Wang X; Ottosson A; Ji C; Feng X; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Haematologica; 2009 Apr; 94(4):470-8. PubMed ID: 19229052
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
19. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
Valentiner U; Haane C; Nehmann N; Schumacher U
Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
[TBL] [Abstract][Full Text] [Related]
20. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Jones MD; Liu JC; Barthel TK; Hussain S; Lovria E; Cheng D; Schoonmaker JA; Mulay S; Ayers DC; Bouxsein ML; Stein GS; Mukherjee S; Lian JB
Clin Cancer Res; 2010 Oct; 16(20):4978-89. PubMed ID: 20843837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]